AAD 2019—Isotretinoin not linked to depression in patients with acne


  • Marielle Fares, Pharm.D.
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Real-world data from the retrospective Research on Adverse Drug events And Reports (RADAR) Program showed no significant difference in the frequency of depression in isotretinoin-treated patients with acne when compared with patients with acne with no exposure to isotretinoin.
  • These data suggest that isotretinoin is not an independent risk factor for depression in patients with acne.

Why this matters

  • Previous studies have suggested a correlation between isotretinoin exposure in acne patients and depression.

Key results

  • In patients with acne, there was no significant difference in depression among patients who received isotretinoin when compared with patients who did not receive isotretinoin.
  • Of 1087 isotretinoin-treated patients, 41 were diagnosed with depression (3.77%).
  • Of 36,929 patients not treated with isotretinoin, 1775 (4.81%) were diagnosed with depression.
  • The median duration of isotretinoin exposure was 5 months.
  • The mean age of isotretinoin patients was 27±8 years, and the mean age of patients with no exposure to isotretinoin was 32±10 years.

Study design

  • Data from 38,016 patients with acne were extracted from the Northwestern Medicine Enterprise Data Warehouse between 2001 and 2017 (1087 patients were treated with isotretinoin and 36,929 had no exposure to isotretinoin) and analyzed.
  • Funding: None.

Limitations

  • Observational, retrospective study.
     

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit